Chemomab Therapeutics (CMMB) has released an update.
Chemomab Therapeutics has reported encouraging outcomes from a Phase 2 trial of CM-101, showcasing significant improvements in primary sclerosing cholangitis (PSC) symptoms, with positive effects on liver stiffness, bilirubin levels, and pruritis. The trial results, demonstrating CM-101’s safety and potential as a disease-modifying treatment, set the stage for a Phase 3 trial following discussions with the FDA. These developments indicate a promising horizon for PSC treatment, a condition currently lacking approved therapies.
For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.
